1.
Survival curves of patients receiving irinotecan-based salvage chemotherapy. Progression-free survival (PFS) (A) and overall survival (OS) (B) from initiation of subsequent irinotecan-based salvage chemotherapy after treatment with camrelizumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.